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ABSTRACT 30 
Background 31 
The role of clothing in the management of eczema (syn. atopic dermatitis, atopic eczema) is poorly understood. 32 
This trial evaluated the effectiveness and cost-effectiveness of silk garments (in addition to standard care) for 33 
the management of eczema in children with moderate to severe disease. 34 
Methods and findings 35 
This was a parallel group randomised controlled, observer-blind trial. Children aged 1 to 15 years with moderate 36 
to severe eczema were recruited from secondary care and the community in five UK centres. 37 
Participants were allocated using on-line randomisation (1:1) to standard care, or standard care plus silk 38 
garments; stratified by age and recruiting centre. Silk garments were worn for 6 months. 39 
Primary outcome (eczema severity) was assessed at baseline, 2, 4 and 6 months, by nurses blinded to treatment 40 
allocation using the Eczema Area and Severity Index (EASI), which was log-transformed for analysis 41 
(intention-to-treat analysis). Safety outcome: number of skin infections.  42 
Three hundred children were randomised (26th Nov 2013 to 5th May 2015): 42% girls, 79% white, mean age 5 43 
years. Primary analysis included 282/300 (94%) children (n = 141 in each group). The garments were worn 44 
more often at night than in the day (median of 81% of nights (25th to 75th centile 57% to 96%) and 34% of days 45 
(25th to 75th centile 10% to 76%)). Geometric mean EASI scores at baseline, 2, 4 and 6 months were 9·2, 6·4, 46 
5·8, 5·4 for silk clothing and 8·4, 6·6, 6·0, 5·4 for standard care. There was no evidence of any difference 47 
between the groups in EASI score averaged over all follow up visits adjusted for baseline EASI score, age and 48 
centre (adjusted ratio of geometric means: 0·95, 95% CI 0·85 to 1·07). This confidence interval is equivalent to 49 
a difference of -1·5 to 0·5 in the original EASI scale units which is not clinically important. Skin infections 50 
occurred in 36/142 (25%) and 39/141 (28%) for silk clothing and standard care respectively. Even if the small 51 
observed treatment effect was genuine, the incremental cost per QALY was £56,881 in the base case analysis 52 
from an NHS perspective, suggesting that silk garments are unlikely to be cost-effective within currently 53 
accepted thresholds. Main limitations: whilst minimising detection bias, use of an objective primary outcome 54 
may have underestimated treatment effects.  55 
Conclusions 56 
Silk clothing is unlikely to provide additional benefit over standard care in children with moderate to severe 57 
eczema. 58 
 59 
  60 
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AUTHOR SUMMARY 61 
Why was the study done? 62 
 Prior to this trial, evidence on the use of silk garments for the management of eczema was limited.  63 
 Three, small randomised controlled trials (RCTs) had been conducted, but these were small (74 64 
participants in total), and at risk of bias. 65 
 The existing evidence was insufficient to guide clinical practice on the use of silk clothing in the 66 
management of eczema, and no cost-effectiveness analyses had been undertaken. 67 
What did the researchers do and find? 68 
 We conducted a pragmatic, observer-blind, randomised controlled trial that recruited 300 children with 69 
moderate to severe eczema and followed them for 6 months. 70 
 Participants were randomised to receive standard eczema care plus silk clothing (100% sericin-free silk 71 
garments (DermaSilk or Dreamskin), versus standard care alone.  72 
 After 6 months, there was no evidence of a difference between the groups in eczema severity (EASI 73 
scores) assessed by research nurses; the 95% confidence interval ranged from 1.5 points favouring silk 74 
clothing to 0.5 points favouring standard care), which is not a clinically important difference. 75 
 Even if the potential small benefit of silk garments was genuine, our analysis suggests that they are 76 
unlikely to be cost-effective within currently accepted thresholds, with an incremental cost per quality 77 
adjusted life year of £56,881. 78 
 79 
What do these findings mean? 80 
 The CLOTHES trial is the first large, independent RCT to have evaluated silk garments for the 81 
management of eczema.  82 
 Results of this trial suggest that silk garments are unlikely to provide additional clinical or economic 83 
benefits over standard care for children with moderate to severe eczema.  84 
 These results provide robust evidence for health commissioners and prescribers to make informed 85 
clinical decisions. 86 
 87 
  88 
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INTRODUCTION 89 
Eczema (syn. atopic dermatitis, atopic eczema) is a chronic, itchy, inflammatory skin condition that is common 90 
throughout the world [1]. Childhood eczema has a substantial impact on the quality of life of children and their 91 
families [2]. Many families are keen to identify new ways of managing the symptoms of eczema using non-92 
pharmacological approaches [3]. 93 
Clothing may play a role in either soothing or exacerbating eczema symptoms, and patients are commonly 94 
advised to avoid wool because of its tendency to worsen itch, and to use cotton or fine weave materials next to 95 
the skin [4]. Specialist clothing is now available on prescription in a variety of forms including sericin-free silk, 96 
viscose, and silver-impregnated fabrics. These garments are claimed to be beneficial for the management of 97 
eczema as they can help to regulate the humidity and temperature of the surface of the skin, are smooth in 98 
texture, and they may reduce skin damage from scratching. Some products have anti-microbial properties that 99 
could help to reduce the bacterial load on the skin, which may be important in eczema [5]. 100 
To date, there have been just three small randomised controlled trials (RCTs) of silk clothing for the 101 
management of eczema [6-8]. These trials involved very few participants (n=22, 30 and 22 participants 102 
respectively), were of generally short duration, did not incorporate an economic evaluation, and were at risk of 103 
bias [9].  104 
In view of the limited evidence for the use of silk clothing, the UK National Institute for Health Research Health 105 
Technology Assessment programme commissioned the CLOTHing for the relief of Eczema Symptoms trial 106 
(CLOTHES Trial). The trial had two main objectives: (i) to assess whether use of silk garments plus standard 107 
eczema treatment reduces severity in children with moderate to severe eczema compared with standard 108 
treatment alone, and (ii) if so, to establish the likely cost-effectiveness of silk garments. 109 
METHODS 110 
The protocol has been published [10] and the protocol (S1 Protocol) and statistical analysis plan are available 111 
(www.nottingham.ac.uk/CLOTHES). The study was approved by Health Research Authority East Midlands - 112 
Nottingham 1 Research Ethics Committee (13/EM/0255), and parents/guardians gave written informed consent 113 
(children gave assent as appropriate). The trial was registered on Current Controlled Trials prior to start of 114 
recruitment (ISRCTN77261365 11 Oct 2013). This study is reported as per CONSORT guidelines (S1 115 
CONSORT checklist). A full trial report is available (http://www.journalslibrary.nihr.ac.uk/hta). 116 
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Study design 117 
The CLOTHES trial was a multi-centre, parallel group, observer-blind, pragmatic RCT of 6 months’ duration. 118 
Children aged 1 to 15 years were randomised (1:1) to receive silk garments plus standard eczema care, or 119 
standard eczema care alone. The primary outcome was assessed by research nurses blinded to the treatment 120 
allocation at baseline, 2, 4 and 6 months. 121 
The trial included a nested qualitative evaluation and health economic analysis.  122 
Changes to the protocol after start of participant recruitment included amendment of the number of FLG 123 
mutations to be included in the genetic analysis, and addition of details of the nested qualitative evaluation. 124 
Recruitment 125 
Recruitment took place in five UK centres: Nottingham University Hospitals NHS Trust; Royal Free London 126 
NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Portsmouth Hospitals NHS 127 
Trust and Isle of Wight NHS Trust. Participants were identified through secondary care, primary care, or in 128 
response to local media advertising.  129 
Children aged 1 to 15 years were enrolled. All had a diagnosis of eczema according to the UK Working Party’s 130 
diagnostic criteria [11] and a score of nine or more on the Nottingham Eczema Severity Score (NESS); denoting 131 
moderate to severe eczema over the last 12 months [12]. All participants had at least one area of active eczema 132 
on part of the body that would be covered by the garments. 133 
Children were excluded if they had taken systemic medication (e.g. ciclosporin, oral corticosteroids) or had 134 
received light therapy for eczema in the preceding 3 months; used wet/dry wraps ≥5 times in the last month; 135 
started a new medication or treatment regimen that may affect eczema in the last month; were currently using 136 
silk clothing for their eczema and were unwilling to stop during the trial; and if they were currently taking part 137 
in another clinical trial. Only one child was enrolled per family.  138 
Interventions 139 
The silk garments used in the trial (Dermasil or Dreamskin) are licensed as a medical device with a CE mark for 140 
use in eczema , denoting that they comply with EU legislation and safety requirements. Two brands were 141 
included to improve the generalizability of the trial findings, to avoid commercial advantage to any one 142 
company, and to limit the financial commitment for the companies who donated the garments.  143 
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The garments are made with antimicrobially-protected, knitted, sericin-free silk (100%). Sericin is removed 144 
from the silk fibres during manufacture because it is a protein that coats the outside of silk fibres and has the 145 
potential to cause allergic reactions. Participants received three sets of garments (long-sleeved vest and leggings, 146 
or body suits and leggings depending on the age of the child), and were instructed to wear the clothing as often 147 
as possible during the day and at night.  148 
Standardised usage instructions were provided and participants were advised to allow topical medications to 149 
absorb into the skin prior to wearing the garments. Replacement garments were provided if they were worn out, 150 
lost, or no longer fitted during the 6-month period of the trial.  151 
Participants in both the intervention and control group continued with their standard eczema care in line with 152 
National Institute for Health and Care Excellence (NICE) guidance [13], including regular emollient-use and 153 
topical corticosteroids (or calcineurin inhibitors) for controlling inflammation. Participants were asked not to 154 
change their standard eczema treatment for the duration of the trial unless medically warranted. If a skin 155 
infection was suspected, participants were advised to contact their normal medical team for confirmation of 156 
diagnosis and subsequent treatment. 157 
Outcomes 158 
Core outcomes as defined by the Harmonizing Outcomes Measures for Eczema (HOME) initiative [14,15] were 159 
included. 160 
Primary outcome 161 
Eczema severity captured using the Eczema Area and Severity Index (EASI) [16], was assessed by trained 162 
research nurses at baseline, 2, 4 and 6 months. Baseline EASI was used as a covariate in the analysis model. 163 
EASI is a validated scale recommended as the core outcome instrument for eczema signs [17]. EASI involves an 164 
evaluation of four eczema signs (erythema (redness), excoriation (scratching), oedema/papulation (swelling and 165 
fluid in the skin) and lichenification (thickening of the skin)), and an assessment of percentage area affected by 166 
eczema in four body regions (head and neck, upper limbs, trunk and lower limbs). Higher scores represent more 167 
severe disease. 168 
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Secondary outcomes 169 
a) Global assessment of eczema by research nurses (Investigator Global Assessment: IGA) [18] and by 170 
participants (Participant Global Assessment: PGA) at baseline, 2, 4 and 6 months, using a 6-point scale 171 
(clear, almost clear, mild, moderate, severe, very severe).  172 
b) Self-reported eczema symptoms using the recommended core outcome instrument, [14] the Patient Oriented 173 
Eczema measure (POEM) which captures frequency of itch, sleep loss, bleeding, weeping/oozing, cracking, 174 
flaking and dryness [19]. Higher scores represent more severe disease. POEM scores were collected weekly 175 
using an on-line questionnaire for 6 months.  176 
c) Three Item Severity scale (TIS) [20] at baseline, 2, 4 and 6 months, assessed by the research nurses at a 177 
representative body site (defined as the most bothersome patch of eczema that was covered by the 178 
garments). 179 
d) Use of eczema treatments: number of days of use of topical steroids, topical calcineurin inhibitors, 180 
emollients and wet / dry wrapping were assessed weekly using an on-line questionnaire. Research nurses 181 
assessed change in eczema treatment regimen at each visit and categorized as no change, neutral change, 182 
reduction, or escalation.  183 
e) Health Related Quality of Life at baseline and at 6 months from the perspectives of the family (Dermatitis 184 
Family Impact (DFI)) [21], the main carer (EuroQol five dimension three level (EQ-5D-3L)) [22], and the 185 
child (Atopic Dermatitis Quality of life preference based index (ADQoL) [23]; Child Health Utility 9D 186 
(CHU-9D) [24] in those aged 5 years and over).  187 
f) Durability of the garments and acceptability of use (at 6 months), and adherence (number of days/nights 188 
garments worn, assessed weekly). 189 
g) Within trial cost-effectiveness from NHS perspective using the ADQoL to estimate Quality-Adjusted Life 190 
Years (QALYs). ADQoL is a preference-based utility instrument with four eczema-specific domains 191 
covering: ability to join in activities, mood, ability to be comforted and sleep-loss. The resulting 16 possible 192 
health states range in utility from 0·356 (worst state) to 0·841 (best state) [23]. 193 
Safety outcomes 194 
a) Skin infections requiring antibiotic or antiviral treatment, and serious adverse events (SAEs) related to 195 
eczema. 196 
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Sample size 197 
Three hundred participants provided 90% power at the 5% significance level (two-tailed) to detect a difference 198 
of 3 points between the groups in mean EASI scores. Although this between-group difference is approximately 199 
half the published minimum clinically important difference for EASI (suggested from one study in adults 200 
receiving systemic therapy) [25], we wanted to be sure that a clinically important difference was not missed. 201 
Sample size was based on repeated measures analysis of covariance; standard deviation (SD) 13, correlation 202 
between EASI scores at different time points of 0·6 and loss to follow up 10%.  203 
Randomisation and blinding 204 
Randomisation was stratified by recruiting hospital and by participants’ age: <2years; 2 to 5 years; and >5 years. 205 
A computer generated pseudo-random code with random permuted blocks of randomly varying size was created 206 
by the Nottingham Clinical Trials Unit.  207 
Research nurses accessed the randomisation website via unique user logins. The sequence of treatment 208 
allocations remained concealed until the database was locked at the end of the study, when it was revealed to 209 
data analysts. 210 
Staff at the co-ordinating centre sent confirmation of treatment allocation to participants (along with the silk 211 
clothing as necessary). Whilst it was not possible to blind participants to their treatment allocation, efforts were 212 
made to minimise expectation bias by emphasising in the trial documents that the evidence supporting the use of 213 
silk garments for eczema was limited, and that it was not yet known if such clothing offered any benefit over 214 
standard care. Participant-facing study documents also avoided the use of value-laden terms such as “specialist” 215 
or “therapeutic” clothing.  216 
In order to preserve blinding of the research nurses, participants were reminded in the study literature and in 217 
their clinic appointment letters/texts not to wear the clothing when they attended clinic, or to mention the 218 
clothing when talking to the research nurses. All questions relating to the acceptability and use of the clothing 219 
were completed by either postal or on-line questionnaires, and telephone and email contact with participants was 220 
made by staff from the co-ordinating centre whenever possible. If the research nurses became un-blinded, this 221 
was recorded.  222 
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FLG genotype analysis  223 
Saliva samples were collected for DNA extraction and FLG genotyping. Only participants of white European 224 
ethnicity were included, because FLG mutations are ethnically specific. Results for the four most prevalent loss-225 
of-function mutations in the white European population (R501X, 2282del4, R2447X and S3247X) were 226 
obtained for 217 individuals and were used to define genotype categories: FLG wild type (no mutations 227 
identified); FLG heterozygotes (one FLG null mutation); and FLG homozygotes or compound heterozygotes 228 
(two FLG null mutations). 229 
Statistical methods 230 
Analyses were carried out by LEB (trial statistician) using Stata/SE 13·1. The main approach to analysis was 231 
modified intention to treat, that is, analysis according to randomised group regardless of adherence to allocation 232 
and including participants who provided at least one follow-up. Estimates of the intervention effect are 233 
presented with 95% confidence intervals and p-values. All regression models included the randomisation 234 
stratification variables (recruiting site and age) as covariates, and baseline scores if measured. Adjusted 235 
differences in means for the intervention group compared to the standard care group are presented for 236 
continuous outcomes, and adjusted risk differences and relative risks for binary outcomes. For outcomes 237 
collected at the 2, 4 and 6 month visit, the effect of the trial garments on eczema severity changing over the 238 
study period was explored by including an interaction term between treatment group and time-point in the 239 
model. As there was no evidence of a differential effect over time for any outcomes, we report a single estimate 240 
per outcome that averages the treatment effect over all time-points.  241 
The primary analysis used a multilevel model with observations at 2, 4 and 6 months nested within participants.  242 
The model used a random intercept and slope at the participant level with an unstructured covariance matrix for 243 
these random effects. The model assumed that missing EASI scores were missing at random given the observed 244 
data. EASI scores were right skewed at all time-points. Diagnostic plots indicated that the assumptions for the 245 
multilevel model on the original EASI scale were not met. The data were log transformed for analysis and the 246 
effect presented as a ratio of geometric means [26, 27]. This ratio was back transformed to the original EASI 247 
scale to facilitate interpretation of findings.  248 
Sensitivity analyses for the primary outcome adjusted for variables that had an observed imbalance between the 249 
groups at baseline; used multiple imputation for missing outcome data; and explored the impact of adherence in 250 
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wearing the clothing by estimating the complier average causal effect (CACE) at 6 months using instrumental 251 
variable regression. 252 
A planned sub-group analysis based on presence or absence of loss-of-function mutations in FLG (which is 253 
associated with impaired skin barrier function and more severe disease), was conducted for the primary outcome 254 
by adding an interaction term between allocated treatment and FLG genotype (none, one, or two FLG null 255 
mutations) to the primary analysis model. 256 
The global assessment scores (IGA and PGA) were dichotomized into ‘clear, almost clear or mild eczema 257 
versus ‘moderate, severe or very severe eczema, and analysed using generalised estimating equations. The mean 258 
weekly POEM scores, percentage of days that topical steroids were used, and quality of life outcomes were 259 
analysed using linear models (weighted according to the number of questionnaires completed for the weekly 260 
POEM and topical steroid use). The TIS was analysed using the multilevel model framework as outlined above 261 
for the primary outcome (not transformed). Changes to treatment regimen were based on whether a participant 262 
had reported treatment escalation over the 6 month RCT period and analysed using a generalised linear model. 263 
Skin infections were analysed using negative binomial regression. SAEs, durability and acceptability of use of 264 
the garments were summarised descriptively. 265 
Adherence in wearing the trial clothing was summarised using the percentage of days and nights that the study 266 
clothing was worn. Participants were classified as being broadly adherent if they wore the trial clothing for at 267 
least 50% of the days or 50% of the nights. This was done for participants where at least half (12/24) of the 268 
weekly questionnaires were completed, and sensitivity analysis explored the impact of different assumptions for 269 
those participants who completed less than 50% of the weekly questionnaires. Adherence with the trial clothing 270 
was explored descriptively according to age and baseline eczema severity using correlation coefficients. 271 
Full details of the analysis are documented in the Statistical Analysis Plan, which was finalised prior to database 272 
lock and release of treatment allocation codes for analysis. 273 
Following concerns that the baseline EASI scores appeared lower than might be expected for children with 274 
moderate to severe eczema , an additional post-hoc analysis was conducted to explore the interaction between 275 
baseline severity and treatment group, by adding an interaction term between allocated group and baseline EASI 276 
score (log transformed and continuous) to the primary analysis model.   277 
 278 
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Patient involvement 279 
Public and patient involvement (PPI) was embedded throughout the CLOTHES trial. Various PPI methods such 280 
as online surveys, discussion groups and patient panels, were used to inform multiple aspects of the trial design 281 
including choice of comparator, eligibility criteria, potential barriers to participation and outcome measures. PPI 282 
members also contributed to the development of patient-facing study materials, and took part in media 283 
interviews to enhance recruitment, A PPI representative was a co-applicant on the grant and was involved in all 284 
stages from trial design through to data interpretation and write up, and another PPI representative was a 285 
member of the Trial Steering Committee.  286 
The study results will be published on the CLOTHES website, and a written summary and child-friendly 287 
animated film will be sent to trial participants. 288 
Health economics 289 
Within-trial economic analysis (conducted by THS using Stata/SE 14·1) compared the costs and QALYs in the 290 
standard care and intervention groups from the perspective of the UK National Health Service (NHS). We 291 
attached published unit costs (UK£2014/15) [28-30] to individual level quantities of resource use (S1 Table), 292 
and estimated the mean cost per participant incorporating the cost of the intervention and wider healthcare 293 
resource use (primary care, secondary care and medications).  294 
QALYs were estimated using linear interpolation and area under the curve analysis, adjusting for baseline 295 
values, age and study centre. A regression-based approach (seemingly unrelated regression equations) [31] was 296 
used for the statistical analysis. The level of uncertainty associated with the decision over which option was 297 
most cost-effective was explored using non-parametric bootstrapping [32] to construct the cost-effectiveness 298 
acceptability curve (CEAC) [33]. Neither costs nor QALYs were discounted.  299 
To test the impact of taking an alternative approach to costing the silk garments, sensitivity analysis included an 300 
estimate of the amount pharmacists are reimbursed for each item of clothing they prescribe. This was based on 301 
the NHS Business Services Authority formula to estimate the actual cost to the NHS. Using the March 2015 302 
tariff data [34], where the average discount was 7.43% and the pharmacist’s professional fee £0.90 per 303 
prescription item, the analysis was re-run. 304 
 305 
 306 
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RESULTS 307 
Recruitment and retention 308 
Three hundred children were randomised between 26th November 2013 and 5th May 2015 (last study visit 21st 309 
October 2015). The primary analysis included 141 participants in each group who had at least one primary 310 
outcome assessment after baseline (Fig 1). For all but four participants, outcome assessments were performed by 311 
the same nurse at all study visits. 312 
Fig 1: Participant flow diagram 313 
For the weekly on-line questionnaires (24 questionnaires over 6 months), 126/149 (85%) in the intervention 314 
group and 127/151 (84%) participants in the standard care group completed 12 questionnaires or more. The 315 
median number completed was 22 (25th to 75th centile 17 to 24) in both groups.  316 
Baseline characteristics 317 
Participants had a mean age of 5 years, 42% were girls and 79% were white. At recruitment, 72% had moderate 318 
or severe AE, as judged by the Investigator Global Assessment (Table 1). Demographic and clinical 319 
characteristics were well balanced at baseline apart from gender and parental reported history of asthma and 320 
food allergy (Table 1). The mean baseline EASI score was slightly higher in the intervention group as more 321 
children had a baseline EASI score of over 30 points (14 participants for intervention; 4 participants for standard 322 
care). However the median and inter-quartile ranges (IQR) were similar between the groups (Table 2).   323 
Table 1: Baseline demographic and clinical characteristics 324 
 325 
 Standard care (n = 151) Intervention (n = 149) Total (n = 300) 
    
Demographics    
Age (years) 
Mean [sd] 
5 [3·6] 5·1 [3·7] 5·1 [3·6] 
Median [25th, 75th centile] 4 [2, 8] 4 [2, 7] 4 [2, 7·5] 
Min, max 1, 14 1, 15 1, 15 
    
Gender     
Boys 82 (54%) 92 (62%) 174 (58%) 
Girls 69 (46%) 57 (38%) 126 (42%) 
    
Ethnicity     
white 123 (81%) 114 (77%) 237 (79%) 
Indian/Pakistani/Bangladeshi 8 (5%) 7 (5%) 15 (5%) 
Black 6 (4%) 6 (4%) 12 (4%) 
Chinese 1 (1%) 3 (2%) 4 (1%)
Other Asian (non-Chinese) 0 (0%) 4 (3%) 4 (1%) 
Mixed Race 12 (8%) 13 (9%) 25 (8%) 
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Other 1 (1%) 2 (1%) 3 (1%) 
    
Clinical characteristics     
History of atopy (self-reported)     
Asthma 57 (38%) 46 (31%) 103 (34%) 
Allergic rhinitis 60 (40%) 56 (38%) 116 (39%) 
Food allergy 80 (53%) 68 (46%) 148 (49%) 
Anaphylaxis 23 (15%) 23 (15%) 46 (15%) 
    
Type of eczema    
Discoid 19 (13%) 17 (11%) 36 (12%) 
Flexural 144 (95%) 147 (99%) 291 (97%) 
    
Location of eczema     
Head and neck 115 (76%) 120 (81%) 235 (78%) 
Hands and wrists 116 (77%) 108 (72%) 224 (75%) 
Feet and ankles 100 (66%) 96 (64%) 196 (65%) 
Limbs 151 (100%) 149 (100%) 300 (100%) 
Trunk 128 (85%) 122 (82%) 250 (83%) 
    
  
Previous medical care    
General practitioner only 41 (27%) 40 (27%) 81 (27%) 
General practitioner and secondary care 110 (73%) 109 (73%) 219 (73%) 
    
Medication used in the month prior to 
randomisation 
   
Emollients 150 (99%) 146 (98%) 296 (99%) 
Topical steroids 136 (90%) 130 (87%) 266 (89%) 
Calcineurin Inhibitors 14 (9%) 15 (10%) 29 (10%) 
Wet/dry wraps (1 to 4 times) 13 (9%) 14 (9%) 27 (9%) 
    
    
Nottingham Eczema Severity Score (NESS)*    
Moderate eczema in last year (9-11) 28 (19%) 30 (20%) 58 (19%) 
Severe eczema in last year (12-15) 123 (81%) 119 (80%) 242 (81%) 
    
Investigator Global Assessment (IGA) on 
day randomised 
   
Almost clear 4 (3%) 2 (1%) 6 (2%) 
Mild 39 (26%) 39 (26%) 78 (26%) 
Moderate 77 (51%) 67 (45%) 144 (48%) 
Severe 30 (20%) 36 (24%) 66 (22%)
Very severe 1 (1%) 5 (3%) 6 (2%) 
    
Patient orientated eczema measure (POEM)*    
Mean [sd] 16·6 [4·8] 17·3 [5·8] 17 [5·4] 
    
FLG genotype$ (using mutations R501X, 
2282del4, R2447X , S3247X)  for white 
ethnicities only                  (n) 
(123) (114) (237) 
no mutations 72 (59%) 71 (62%) 143 (60%) 
one FLG null mutation 31 (25%) 20 (18%) 51 (22%) 
two FLG null mutations 12 (10%) 11 (10%) 23 (10%) 
Not known 8 (7%) 12 (11%) 20 (8%) 
Health Care Resource use (UK£2014/15) (4 
weeks pre-trial)                      mean[SD] 
£34.82 (69.14) £35.60 (69.46) £35.20 (69.17)) 
Data are n (%) unless otherwise specified.  326 
Categories for history of eczema, type of eczema and location of eczema are not mutually exclusive. 327 
* Higher values represent more severe AE 328 
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$ For children, where informed consent for genetic study was given and the saliva sample was taken. Data are 329 
presented for white European ethnicities only as FLG mutations are population-specific and mutations tested are 330 
prevalent in white European individuals. 331 
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Table 2: Outcomes assessed during clinic visits  
 
Outcome and allocated group Baseline  2 month 4 months 6 months Adjusted intervention 
effect*Intervention - standard care (95% 
CI) 
      
BLINDED OUTCOMES      
Eczema area and severity index 
(primary outcome) 
     
Standard care      
n 151 137 133 139  
Median [25th, 75th centile] 7·3 [4·2, 12] 5·3 [2·5, 10·5] 4·3 [2·1, 10] 4·2 [2, 9·2]  
Geometric mean 8·4 6·6 6·0 5·4  
Intervention     Ratio of geometric means 0·95 (0·85, 
1·07), p = 0·43 n 149 139 135 133 
Median [25th, 75th centile] 7 [4·1, 15·4] 4·9 [2·2, 9·9] 4·1 [2·2, 9·4] 4 [1·9, 7·9] 
Geometric mean 9·2 6·4 5·8 5·4 
     
     
Three item severity scale (TIS) – 
mean [sd] (n)  
    Difference in means 0·09 (-0·22, 0·40), 
p = 0·57 
Standard care   4·9 [1·8] (n = 151) 4·0 [1·9] (n = 137) 4·1 [2·2] (n = 133) 3·7 [1·9] (n = 139) 
Intervention  4·9 [1·8] (n = 149) 4·1 [2·0] (n = 139) 4·1 [2·1] (n = 136) 3·7 [2·0] (n = 134) 
      
      
Investigator global assessment 
(IGA) of moderate, severe or very 
severe eczema – n (%) 
    Risk difference       
-0·1% (-9·3%, 
6·3%), p = 0·70 
Relative risk 
0.98 (0.82, 1.12), 
p = 0.63 
Standard care  108/151 (72%) 72/137 (53%) 63/133 (47%) 56/139 (40%) 
Intervention  108/149 (72%) 71/139 (51%) 60/136 (44%) 58/134 (43%) 
      
UNBLINDED OUTCOMES      
Participant global assessment 
(PGA) of moderate, severe or very 
severe eczema – n (%) 
    Risk difference       
-10·1%, (-18·3%,    
-2·0%), p = 0·01 
Relative risk 
0.83 (0.70, 0.98), 
p = 0.03 
Standard care  113/151 (75%) 82/137 (60%) 72/133 (54%) 60/139 (43%) 
Intervention  98/149 (66%) 62/139 (45%) 56/135 (41%) 51/134 (38%) 
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Treatment escalation since 
previous visit – n (%) 
    Risk difference (any 
escalation$) -5·3%  
(-16·3%, 5·7%), p = 
0·34 
Relative risk 
(any escalation$) 
0.87 (0.62, 1.22), 
p = 0.43 
Standard care  - 34/137 (25%) 16/133 (12%) 16/139 (12%)
Intervention  - 15/139 (11%) 16/136 (12%) 16/134 (12%) 
      
Quality of life outcomes#       
Dermatitis Family Impact 
Questionnaire (DFI)  mean [SD] (n) 
    Difference in means -0·8 (-2·1, 0·4), p = 
0·18 
Standard care  12·0 [6·3] (n= 151) N/A N/A 8·6 [6·8] (n = 138) 
Intervention  12·4 [6·6] (n= 149) N/A N/A 7·6 [6·1] (n = 133) 
      
Atopic Dermatitis Quality of Life 
(ADQoL) # mean [SD] (n) 
     
Standard care 0·6952 [0·1300] (151) N/A N/A 0·7292 [0·1308](139) Difference in means 0·0260 (-0·0018, 
0·0539), p = 0·07 Intervention 0·6883 [0·1409] (149) N/A N/A 0·7515 [0·1273](134) 
CHU-9D# (5years and over only) 
mean [SD] (n) 
     
Standard care 0·8292 [0·1263] (n=64) N/A N/A 0·8828 [0·1059](67) Difference in means -0·0243 (-0·0584, 
0·0098), p= 0·16 Intervention 0·8386 [0·1115] (n=70) N/A N/A 0·8677 [0·1114](65) 
 
EQ-5D-3L index# for parents HRQL 
mean [SD] (n) 
     
Standard care 0·8983 [0·1612] (151) N/A N/A 0·9107 [0·1529] (138) Difference in means 0·0115 (-0·0185, 
0·0415), p = 0·45 Intervention 0.9018 [0.1710] (147) N/A N/A 0.9184 [0.1564] (134) 
*  - 282 participants were included in the analysis  model for the EASI (n = 141 each group, note one participant in the intervention group attended 2 follow-up visits but EASI was not fully 
assessed at either of these visits as the child and parent did not want lower limbs assessed).  283 participants were included in the analysis models for the global assessments and TIS (n = 141 
standard care, n = 142 intervention). 271 participants were included in the analysis model for DFI (n = 138 standard care, n = 133 intervention).  All analyses were adjusted for site, age, and 
baseline value of the outcome if it was measured. 
 
$ - Treatment escalation analysed as any treatment escalation between baseline and 6 months: 50/140 participants (36%) in the standard care group and 42/138 (30%) in the intervention group. 
Participants who missed visits were included if they had an escalation at any of the visits they attended or if they attended the 6 month visit and there was neutral or no change or a reduction in 
treatment.  
 
#  Ranges for quality life scores: DFI (0 to 30); ADQoL (0.356 to 0.841); CHU-9D (0.33 and 1); EQ-5D-3L (-0.594 to 1) 
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Adherence, contamination and blinding 
Adherence in wearing the garments was good. The garments were worn more often at night than in the 
day (median of 81% of nights (25th to 75th centile 57% to 96%) and 34% of days (25th to 75th centile 
10% to 76%)) (Fig 2 and S2 Table). Adherence in wearing the garments was not associated with age or 
eczema severity at baseline (S2 Table). Contamination of the standard care group was low; six 
participants reported wearing silk clothing during the trial (including one participant who was allocated 
to the standard care group but was sent the silk clothing in error. This participant was included in the 
analysis according to randomised allocation). 
Fig 2: Mean number of days/nights trial garments worn each week 
 
The percentage of participants that escalated their eczema treatment during the 6-month trial was 
similar in the two groups (Table 2). 
Acceptability of the garments assessed at 6 months suggested that 85/121 (70%) were satisfied or very 
satisfied with the clothing (95% CI 61% to 78%), and 89/121 (74%) of participants were either happy 
or very happy to wear the garments (95% CI 64% to 81%). Some participants raised concerns about the 
garments including poor durability and fit. 
Research nurses remained blinded to treatment allocation for 289/300 (96%) of participants. 
Unblinding occurred for three participants in the standard care group and eight in the intervention 
group.  
Primary outcome 
For the primary outcome of eczema severity, there was no difference between the groups in the nurse-
assessed EASI scores. For EASI scores averaged over the 2, 4 and 6-month follow-up visits, the 
adjusted ratio of geometric means was 0·95 (95% CI 0·85 to 1·07; p = 0·43) (Table 2 and Fig 3). This 
confidence interval equates to a difference of approximately -1·5 to 0·5 points in the original EASI 
scale units. 
Fig 3: Primary outcome: Geometric mean nurse-assessed eczema severity (EASI scores) with 95% 
confidence intervals 
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All sensitivity analyses for the primary outcome (adjusting for additional baseline factors, imputing 
missing values and exploration of the impact of adherence (CACE analysis)) were supportive of the 
primary analysis (S3 Table). There was no differential effect of the clothing on EASI eczema severity 
according to FLG subgroup (S4 Table) or severity of eczema at baseline (S5 Table).  
 
Secondary outcomes 
For the secondary outcomes, there were no between group differences in nurse-assessed eczema 
severity (IGA, TIS), quality of life (DFI, EQ-5D-3L, CHU-9D), or medication use (percentage of days 
eczema medications used, or escalation of eczema treatments) (Tables 2 and 3). However, small 
differences were observed for two of the participant-reported secondary outcomes of eczema severity 
(PGA, POEM) (Tables 2 and 3; Fig 4). 
Table 3: Secondary outcomes assessed on weekly questionnaires  
 
 
 Standard care(n = 
147) 
Intervention(n = 145) Adjusted 
difference  in 
means 
Intervention – 
standard 
care(95% CI) 
    
Participant mean of weekly POEM 
score during the 6 month RCT # 
   
Mean [SD] 14·2 [5·5] 11·6 [5·6] -2·8  (-3·9, -1·8), 
p < 0·001 
    
Percentage of days topical steroids 
used$ 
   
Mean [SD] 44·1 [28·2] 39·3  [27·8] -3·7  (-9·6, 2·3), 
p = 0·23 
    
Percentage of days emollients 
used*mean [SD] 
88·4   [20·1] 86·0  [22·1]  
    
Percentage of days calcineurin 
inhibitors used^  
   
Mean [SD] 5·8 [15·9] 5·7 [16·3]  
    
Percentage of days wet/dry wraps  
used^ 
   
Mean [SD] 5·2   [17·1] 3·1 [12·5]  
    
Table shows data for participants who completed at least one questionnaire 
Summary statistics and analyses reported are weighted according to the number of questionnaires completed. 
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# Difference in means adjusted for baseline POEM score and stratification variables age and site 
 
$ Difference in means adjusted for topical steroid use at baseline (yes/no) and stratification variables age and site. 
 
* Between group analysis not done as assumptions for model not met, as most participants were using these most of the time. 
 
^ Assumptions were not met due to the large number of participants that weren’t using these treatments.  
  
 
 
Fig 4: Mean weekly patient-reported symptoms (POEM scores) with 95% confidence intervals 
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Safety outcomes (number of skin infections and hospitalizations due to eczema) were similar in the two 
groups (Table 4).  
Table 4: Safety outcomes  
 
 Standard care(n = 
141) 
Intervention(n = 
142) 
Adjusted relative risk 
Intervention - standard 
care (95% CI) 
    
Any skin infection during 6-month 
RCT – n (%)# 
39 (28%) 36 (25%) 0·89 (0·54, 1·47), p = 
0·66 
   
Number of skin infections per 
participant 
   
Median [25th, 75th centile] 1 [1, 2] 1 [1, 2]  
Min, max 1, 5 1, 8  
n 39 36  
    
Number of inpatient stays per 
participant due to eczema – n (%) 
   
0 139 (99%) 138 (97%) 
1 1 (1%) 2 (1%) 
2 1 (1%) 2 (1%) 
3 or more 0 0 
   
# Relative risk for skin infections adjusted for stratification variables age and site. 
Table shows data for participants who attended at least one follow-up visit 
Percentages for any skin infection and inpatient stay use the number of participants attending at least one follow-up visit as the 
denominator.  
Skin infections were reported by the parent/main carer and defined as any skin infections that required treatment with antivirals 
or antibiotics.  
Inpatient hospital stays for eczema (for any reason) were reported by the parent/main carer. 
Cost-effectiveness 
The economic evaluation included all participants with complete resource use and ADQoL data at 
baseline and 6 months (n=273). The cost of a single set of tops and leggings ranged from £66.02 to  
£155.49, depending on the size of the child. The mean cost of silk garments for 6 months, including 
initial and replacement garments, was £318.52 (SD: £136.60) per participant in the base case (Table 5). 
The mean number of sets of garments (tops and leggings) per participant in the base case was 4·15 (SD 
1.56). Sixty-one (45.54%) intervention participants received replacement garments over the 6 months.  
Combined with wider health resource use, the adjusted mean difference in cost per participant was 
£364.94 (95% CI £217.47 to £512.42: p < 0·001) for those who received silk garments compared to 
those who did not in the base case (Table 5). The difference in total costs between groups reflects the 
cost of the intervention, wider NHS costs were not significantly different between groups (£48.57 
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higher per participant on average in the intervention group, 95% CI -105.92, 203.05: p=0·537). For 
resource use and costs for all resource items see S6 Table and S7 Table.  
The adjusted mean difference in QALY per participant was 0.0064 (95% CI  
-0.0004, 0.0133: p = 0·07) (Table 5). The adjusted incremental cost per QALY was £56,811, 
suggesting that silk garments for AE are not cost-effective within currently accepted thresholds. At a 
willingness to pay of £30,000 per QALY the probability of silk garments being cost effective was 
12.13%. This conclusion did not change in sensitivity analysis testing an alternative approach to 
costing the silk garments. Although the cost of silk garments reduced, at £53,989 per QALY, the 
estimated incremental cost per QALY was still over the accepted NICE threshold value (see S8 Table). 
Table 5: Key findings from the base case economic evaluation (UK£2014/15) 
 
 
Outcome Standard 
caren=139 Mean 
(SD) 
Intervention 
n=134 Mean (SD) 
Unadjusted (Adjusted) mean 
difference intervention – 
standard care (95% CI) 
HEALTH 
OUTCOMES 
   
Utility (ADQoL)    
Baseline 0·6959 (0·1288) 0·6879 (0·1418)  -0·0081 (-0·0404, 0·0241) 
6 months 0·7292 (0·1308)  0·7515 (0·1273) 0·0224 (-0·0084, 0·0531) 
QALYs     
Over 6 months 0·3563 (0·0562)  0·3598 (0·0561) 0·0036 (-0·0098, 
0·0169),(0·0064  (-0·0004,  
0·0133)) 
    
COSTS    
Garments 0·00 (0·00) 318.52  (136.60) 318.52 (295.71, 341.33) 
Primary care visits 47·01 (73·71) 36·52 (57·74) -10·49 (-26·30, 5·33) 
Secondary care 
visits 
153·00 (327·13) 213·09 (604·47) 60·09 (-55·16, 175·34) 
Prescriptions 120.86 (243.81) 119.82 (244.67) -1.04 (-59.25, 57.18) 
Total healthcare 
costs, excluding 
garments 
320.86 (446.13) 369.43 (805.88) 48.57 (-105.92, 203.05) 
Total healthcare 
costs, including 
garments 
320.86 (446.13) 687.96 (809.27) 367.09  (212.12, 522.07) (364.94 
(217.47,512.42)) 
 
Incremental Costs Effectiveness Ratio (ICER) = £56,811per QALY 
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DISCUSSION 
Main findings 
This trial found little evidence of clinical or economic benefit of using silk garments in addition to 
standard care, compared with standard care alone in children with moderate to severe eczema. There 
were no differences between the treatment groups for any of the outcomes that were assessed by 
research nurses who were unaware of participants’ treatment allocation, and the percentage of days on 
which topical corticosteroids or calcineurin inhibitors were used did not differ between the groups. The 
95% confidence intervals around the primary efficacy estimates were narrow, suggesting that a 
clinically important treatment effect is unlikely to have been missed, and sensitivity analyses (imputing 
missing values, adjusting for baseline imbalances and exploring the impact of adherence in wearing the 
garments) supported the primary analysis.  
Sub-group analysis based on FLG genotype showed no evidence of differential treatment response in 
children with an inherited impairment in skin barrier function, and a post-hoc analysis exploring the 
impact of baseline severity on the primary outcome showed no effect; suggesting that children with 
more severe disease were no more likely to benefit from silk clothing than those with milder disease. 
The trial garments are marketed as possessing antimicrobial properties, but this study found no 
evidence to suggest a reduction in the number of skin infections in those using the clothing compared 
to those randomised to standard care alone. 
Of the seven unblinded secondary outcomes, two (POEM and PGA) showed small differences in 
favour of the silk garments, most noticeably in the first 3-months of the trial. Whilst these small 
differences could have been genuine, they are most likely due to an expectation bias that declined with 
time. Our nested qualitative study (to be reported separately), highlighted the hopes that both children 
and parents placed on the silk clothing. A previous eczema trial has reported differences between 
blinded and unblinded outcomes when expectation in the benefits of the trial intervention is high [35]. 
Relevance to other studies 
There have been no further RCTs on the effectiveness of silk garments for eczema since the CLOTHES 
trial began (search updated 14th March 2016), and meta-analysis of the available silk clothing trials is 
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not possible due to heterogeneity of designs. Additional brands of silk garments have since become 
available for use in eczema (e.g. SkinniesTM), but these have not been formally evaluated in RCTs. At 
the time of commissioning this research (2011), £840,272 was spent on prescriptions for silk garments 
per annum in the UK (for all indications). By 2014, this amount had risen to £2,082,810 per annum 
[36-39]. 
Strengths and limitations 
The CLOTHES Trial was an adequately powered RCT, with high follow-up rates and good adherence. 
The pragmatic study design meant that use of silk garments was evaluated as they might be used in 
normal practice, with mixed patterns of adherence. The trial placed special emphasis on objective 
outcome measures in order to minimise response bias.  
It is possible that our emphasis on objective eczema severity outcomes meant that some important 
potential benefits were not captured in the primary analysis. Other factors, such as improvements in 
quality of life, or a reduction in symptoms (especially itch and sleep loss, as measured by POEM), may 
be important drivers in determining whether or not patients feel that the garments are helpful. 
Nevertheless, we found no evidence of improved quality of life amongst trial participants using a range 
of validated scales.  
Eczema severity scores improved for both groups during the trial, probably due to a combination of 
regression to the mean, and regular monitoring of the eczema resulting in enhanced adherence to 
standard care. It is possible that treatment effects were masked by these general trial effects.  
Generalisability 
The study has strong external validity as it was pragmatic in design to reflect normal clinical practice, 
and participants were recruited from five UK centres covering a range of urban and rural settings. We 
recruited children with a range of eczema severities but the majority had moderate to severe disease, 
and 32% had at least one mutation on the gene encoding for FLG; a proportion typical of eczema 
patents with moderate or severe disease [35]. Overall, 49% had self-reported food allergy and 15% 
reported a history of anaphylaxis, which is high for children with moderate to severe disease. However, 
these data were collected by self-report and so may include food intolerance as well as food allergy.  
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We are unable to comment on effectiveness of the silk garments if used continuously day and night, 
although sensitivity analysis found no evidence of improved outcomes in those who adhered more fully 
in wearing the garments.  It is also possible that the beneficial effects of silk garments are best realised 
during a period of eczema flare, and daily use of the garments in the CLOTHES trial could have led to 
more rapid deterioration of the clothing than might have been seen if the garments were worn 
occasionally when the eczema was at its worst. 
Conclusion 
This is the first large, independent trial to have evaluated silk garments for the management of eczema. 
The nested economic evaluation suggests that use of these garments is unlikely to be cost-effective for 
health providers, even if the small observed benefits were genuine. These trial results provide health 
commissioners with a better evidence-base on which to make informed decisions about silk garments 
for eczema. Whether or not parents feel that the small benefits identified in some of the secondary 
outcomes are sufficient to justify purchasing these garments is something for individuals to consider on 
a case-by-case basis. 
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